How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,190 results for

Benign Prostatic Hyperplasia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Re: A Prospective Randomised Placebo-Controlled Study of the Impact of Dutasteride/Tamsulosin Combination Therapy on Sexual Function Domains in Sexually Active Men with Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH). (Abstract)

Re: A Prospective Randomised Placebo-Controlled Study of the Impact of Dutasteride/Tamsulosin Combination Therapy on Sexual Function Domains in Sexually Active Men with Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH). 31009965 2019 05 09 2019 05 09 1527-3792 201 5 2019 05 The Journal of urology J. Urol. Re: A Prospective Randomised Placebo-Controlled Study of the Impact of Dutasteride/Tamsulosin Combination Therapy on Sexual Function Domains in Sexually (...) Active Men with Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH). 833-834 10.1097/01.JU.0000554112.39991.bd Kaplan Steven A SA eng Journal Article Comment United States J Urol 0376374 0022-5347 G3P28OML5I Tamsulosin O0J6XJN02I Dutasteride AIM IM BJU Int. 2018 Apr;121(4):647-658 29044968 Dutasteride Humans Lower Urinary Tract Symptoms Male Prospective Studies Prostatic Hyperplasia Tamsulosin 2019 4 24 6 0 2019 4 24 6 0 2019 5 10 6 0 ppublish 31009965 10.1097/01.JU

2019 The Journal of urology Controlled trial quality: uncertain

162. Erratum: Efficacy of tamsulosin and tadalafil in relieving benign prostatic hyperplasia related symptoms: A randomized double blind placebo controlled cross-over study. (Abstract)

Erratum: Efficacy of tamsulosin and tadalafil in relieving benign prostatic hyperplasia related symptoms: A randomized double blind placebo controlled cross-over study. [This corrects the article on p. 25 in vol. 35, PMID: 30692721.].

2019 Indian journal of urology : IJU : journal of the Urological Society of India Controlled trial quality: uncertain

163. Re: rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: 4-Year Results from Randomized Controlled Study. (Abstract)

Re: rezÅ«m Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: 4-Year Results from Randomized Controlled Study. 30973301 2019 06 13 2019 06 13 1527-3792 202 1 2019 07 The Journal of urology J. Urol. Re: rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: 4-Year Results from Randomized Controlled Study. 5 10.1097/JU.0000000000000260 Kaplan Steven A SA eng Journal Article Comment (...) 2019 06 07 United States J Urol 0376374 0022-5347 0 Steam AIM IM Urology. 2019 Apr;126:171-179 30677455 Humans Hyperthermia, Induced Lower Urinary Tract Symptoms Male Prostatic Hyperplasia Steam 2019 4 12 6 0 2019 6 14 6 0 2019 4 12 6 0 ppublish 30973301 10.1097/JU.0000000000000260

2019 The Journal of urology Controlled trial quality: uncertain

164. Influence of alpha-adrenoceptor antagonists therapy on stool form in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. (Full text)

Influence of alpha-adrenoceptor antagonists therapy on stool form in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. To evaluate the short-term efficacy and safety of two α1-adrenoceptor (AR) antagonists, tamsulosin and silodosin, in treating patients with untreated lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH), with a focus on stool form.This study was a non-blinded, open-label, prospective randomized comparative study (...) . Tamsulosin or silodosin was administered to patients with untreated LUTS/BPH, and their efficacy and safety in the early stage of treatment were compared using the questionnaire of International Prostate Symptom Score (IPSS)/quality of life (QOL), the Gastrointestinal Symptom Rating Scale (GSRS), and the Bristol Stool Form Scale (BSFS).The per protocol set consisted of 22 patients in tamsulosin group (mean age, 70.15 ± 5.70 years) and 20 patients in silodosin group (73.00 ± 6.48 years). The total IPSS

2019 Lower urinary tract symptoms Controlled trial quality: uncertain PubMed abstract

165. Resveratrol induces apoptosis of benign prostatic hyperplasia epithelial cell line (BPH-1) through p38 MAPK-FOXO3a pathway. (Full text)

Resveratrol induces apoptosis of benign prostatic hyperplasia epithelial cell line (BPH-1) through p38 MAPK-FOXO3a pathway. Resveratrol is reported to inhibit the growth of prostate, which is characteristic of benign prostatic hyperplasia (BPH) condition. However, the mechanism remains unclear. This study aimed to identify the effects and probable mechanism of resveratrol on BPH.We used the BPH epithelial cell line BPH-1 to investigate the effect of resveratrol. Cells were treated with various

2019 BMC Complementary and Alternative Medicine PubMed abstract

166. Efficacy and safety of tadalafil 5 mg once-daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double-blind, parallel, placebo- and tamsulosin-controlled (Full text)

Efficacy and safety of tadalafil 5 mg once-daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double-blind, parallel, placebo- and tamsulosin-controlled To evaluate the efficacy and safety of tadalafil in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction.The present phase 3, randomized, double-blind, parallel, placebo (...) in the tadalafil versus placebo group at 12 weeks (23.87% vs 10.90%; P < 0.001 and 36.62% vs 15.96%; P < 0.001, respectively). Safety results were consistent with the known tadalafil safety profile.Tadalafil is efficacious and well tolerated in the treatment of Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction.© 2018 The Japanese Urological Association.

2019 International journal of urology : official journal of the Japanese Urological Association Controlled trial quality: predicted high PubMed abstract

167. First-in-man Safety and Efficacy of the ClearRing Implant for the Treatment of Benign Prostatic Hyperplasia. (Abstract)

First-in-man Safety and Efficacy of the ClearRing Implant for the Treatment of Benign Prostatic Hyperplasia. Although effective for benign prostatic hyperplasia (BPH), transurethral resection of the prostate (TURP) can be associated with side effects including prolonged recovery, storage and voiding symptoms, and a risk of acute urinary retention.To test a new minimally invasive device for the treatment of lower urinary tract symptoms (LUTS) due to BPH, involving implantation of a C-shaped (...) model was fitted to IPSS, the Quality of Life (QOL) scale, Benign Prostatic Hyperplasia Impact Index, maximum flow rate (Qmax), and postvoid residual volume. Statistical significance was defined as p<0.05.The average age was 71.4 yr, prostate size was 35-50cm3, and IPSS was 21.6. All procedures were successfully completed with one implant in 28 patients and two implants in one patient. No serious complications occurred. Patients experienced symptom relief by 3 mo that was sustained to 12 mo. Mean

2018 European urology focus Controlled trial quality: uncertain

168. Editorial Comment to Efficacy and safety of tadalafil 5 mg once-daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double-blind, parallel, placebo- and (Full text)

Editorial Comment to Efficacy and safety of tadalafil 5 mg once-daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double-blind, parallel, placebo- and 30362175 2019 02 15 2019 02 15 1442-2042 26 2 2019 02 International journal of urology : official journal of the Japanese Urological Association Int. J. Urol. Editorial Comment to Efficacy and safety of tadalafil 5 mg once-daily in Asian men (...) with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double-blind, parallel, placebo- and tamsulosin-controlled study. 200-201 10.1111/iju.13833 Kitta Takeya T Department of Renal and Genitourinary Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan. eng Editorial Comment 2018 10 25 Australia Int J Urol 9440237 0919-8172 742SXX0ICT Tadalafil G3P28OML5I Tamsulosin IM Int J Urol. 2019 Feb;26(2

2019 International journal of urology : official journal of the Japanese Urological Association Controlled trial quality: uncertain PubMed abstract

169. Effectiveness of the addition of tadalafil to tamsulosin in the treatment of acute urinary retention in patients with benign prostatic hyperplasia: A randomized clinical trial. (Abstract)

Effectiveness of the addition of tadalafil to tamsulosin in the treatment of acute urinary retention in patients with benign prostatic hyperplasia: A randomized clinical trial. Acute urinary retention is one of the most significant complications of benign prostatic hyperplasia. Until now, standard treatments include catheterization and use of α-blockers. Tadalafil has been recently seen to also play a role in the treatment of urinary symptoms caused by benign prostatic hyperplasia. The aim (...) of this study was to survey the addition of tadalafil to tamsulosin in the treatment of acute urinary retention in patients with benign prostatic hyperplasia.This is a randomized, double-blind placebo-controlled clinical trial. In all, 80 patients with benign prostatic hyperplasia-related acute urinary retention referred to the emergency department of the hospital were divided into two groups of 40 each and randomly assigned to receive either 0.4 mg tamsulosin plus placebo or 0.4 mg tamsulosin plus 10 mg

2019 Urologia Controlled trial quality: predicted high

170. Rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study. (Full text)

RezÅ«m Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study. To report 4-year outcomes of the randomized controlled trial of water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms due to benign prostatic hyperplasia.Total 188 subjects; 135 men ≥50 years old, International Prostate Symptom Score ≥ 13, maximum flow rate (Qmax) ≤15 mL/s and prostate volume 30 (...) to 80 cc treated with Rezūm System thermal therapy were followed 4 years; subset of 53 men who requalified for crossover from control to active treatment were followed 3 years.Lower urinary tract symptoms were significantly improved within ≤3 months after thermal therapy and remained consistently durable (International Prostate Symptom Score 47%, quality of life 43%, Qmax 50%, Benign Prostatic Hyperplasia Impact Index 52%) throughout 4 years (P <.0001); outcomes were similarly sustained in crossover

2019 Urology Controlled trial quality: uncertain PubMed abstract

171. Evaluating the effects of switching from dutasteride to tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms: A randomized, open-label, multicenter study. (Full text)

Evaluating the effects of switching from dutasteride to tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms: A randomized, open-label, multicenter study. 30659664 2019 01 19 1442-2042 2019 Jan 18 International journal of urology : official journal of the Japanese Urological Association Int. J. Urol. Evaluating the effects of switching from dutasteride to tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms: A randomized, open

2019 International journal of urology : official journal of the Japanese Urological Association Controlled trial quality: uncertain PubMed abstract

172. Re: A Prospective Randomised Placebo-controlled Study of the Impact of Dutasteride/Tamsulosin Combination Therapy on Sexual Function Domains in Sexually Active Men with Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH). (Abstract)

Re: A Prospective Randomised Placebo-controlled Study of the Impact of Dutasteride/Tamsulosin Combination Therapy on Sexual Function Domains in Sexually Active Men with Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH). 30391083 2019 03 04 2019 03 04 1873-7560 75 2 2019 02 European urology Eur. Urol. Re: A Prospective Randomised Placebo-controlled Study of the Impact of Dutasteride/Tamsulosin Combination Therapy on Sexual Function Domains in Sexually Active Men (...) with Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH). 344-345 S0302-2838(18)30826-1 10.1016/j.eururo.2018.10.034 Moncada Ignacio I Department of Urology, Hospital Universitario La Zarzuela, Madrid, Spain. Electronic address: ignacio@moncada.name. Krishnappa Pramod P Department of Urology, Hospital Universitario La Zarzuela, Madrid, Spain; Department of Urology, NU Hospitals, Bangalore, India. eng Journal Article Comment 2018 10 31 Switzerland Eur Urol 7512719 0302-2838

2019 European Urology Controlled trial quality: uncertain

173. Re: Moxibustion as an Adjuvant for Benign Prostatic Hyperplasia with Lower Urinary Tract Symptoms: A Protocol for a Parallel-Group, Randomised, Controlled Pilot Trial. (Abstract)

Re: Moxibustion as an Adjuvant for Benign Prostatic Hyperplasia with Lower Urinary Tract Symptoms: A Protocol for a Parallel-Group, Randomised, Controlled Pilot Trial. 28505928 2019 02 13 2019 02 15 1527-3792 197 6 2017 06 The Journal of urology J. Urol. Re: Moxibustion as an Adjuvant for Benign Prostatic Hyperplasia with Lower Urinary Tract Symptoms: A Protocol for a Parallel-Group, Randomised, Controlled Pilot Trial. 1530-1531 S0022-5347(17)39305-9 10.1016/j.juro.2017.03.086 Kaplan Steven (...) A SA eng Journal Article Comment 2017 03 17 United States J Urol 0376374 0022-5347 0 Adjuvants, Immunologic AIM IM BMJ Open. 2015 Dec 11;5(12):e008338 26656981 Adjuvants, Immunologic Humans Lower Urinary Tract Symptoms Male Moxibustion Pilot Projects Prostatic Hyperplasia 2017 5 17 6 0 2017 5 17 6 0 2019 2 14 6 0 ppublish 28505928 S0022-5347(17)39305-9 10.1016/j.juro.2017.03.086

2019 The Journal of urology Controlled trial quality: predicted high

174. What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)? (Full text)

What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)? Though clinical benign prostatic hyperplasia (BPH) is a common disease worldwide, there is still much confusion in the literature and the many clinical guidelines as to its definition. Often the disease is associated with lower urinary tract symptoms (LUTS) and managed according to only symptoms. This leads to undertreatment in some patients with severe bladder outlet obstruction (BOO) with no symptoms (...) , and overtreatment in patients with LUTS but no clinical BPH.Fundamentally, a disease can be defined as an abnormal structure or function or a condition which may cause harm to the organism.Thus, clinical BPH can be defined as prostate adenoma/adenomata, causing a varying degree of BOO, which may eventually cause harm to the patients. With this definition, we are then able to differentiate the disease clinical BPH from the many other less common causes of LUTS, and then treat it according to its

2019 World journal of urology PubMed abstract

175. Efficacy and Safety of Serenoa repens Extract among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. (Abstract)

Efficacy and Safety of Serenoa repens Extract among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. To evaluate the efficacy and safety of Serenoa repens among patients with benign prostatic hyperplasia (lower urinary tract symptoms/benign prostatic hyperplasia [LUTS/BPH]) in China.We conducted a double blind, placebo-controlled study of 354 patients with LUTS/BPH from 19 institutions, to evaluate the efficacy and safety (...) of Serenoa repens. Participants were randomly assigned (1:1) into the Serenoa repens extract (320 mg) or placebo groups for 24 weeks. Primary efficacy parameters were changes in International Prostate Symptom Score and peak urinary flow from baseline to each assessment. Secondary efficacy parameters included improvement of storage symptom and voiding symptom scores, prostate volume, urinary frequency, and total prostate-specific antigen level. Other parameters assessed were quality of life score, a four

2019 Urology Controlled trial quality: predicted high

176. Effect of benign prostatic hyperplasia on the development of spine, hip, and wrist fractures. (Abstract)

Effect of benign prostatic hyperplasia on the development of spine, hip, and wrist fractures. Benign prostatic hyperplasia is one of the most common diseases in the elderly male population. The urinary tract symptoms may increase the risk of falls and fractures. The results indicated that patients with benign prostatic hyperplasia could increase the risk of vertebral compression fractures in both the thoracic and lumbar spine and also hip fractures, but did not increase the risk of wrist (...) fracture.The relationship between benign prostatic hyperplasia and the development of fall-related fractures, especially vertebral compression fractures, has been seldom mentioned in the literature. This study aimed to evaluate the risk of developing vertebral compression fracture, hip fracture, and wrist fracture in patients with benign prostatic hyperplasia.This study obtained claims data retrospectively from the National Health Insurance Research Database of Taiwan and identified 48,114 patients who

2019 Osteoporosis International

177. 'En Bloc' HoLEP with early apical release in men with benign prostatic hyperplasia. (Abstract)

'En Bloc' HoLEP with early apical release in men with benign prostatic hyperplasia. HoLEP represents an excellent treatment option for benign prostatic hyperplasia. Recently, 'en bloc' techniques resulting in improved visualization, shorter surgical times, and easier recognition of the dissection plane have been described. In this paper we describe the 'En bloc' HoLEP technique with early apical release.Between January 2015 and March 2017, 137 consecutive patients were subjected (...) to this technique by a single surgeon. The following parameters were measured pre- and post-procedure: International Prostate Symptom Score (IPSS), maximum flow rate (Qmax), post-void residual urine (PVR) and PSA. Complications were recorded.Mean (SD; range) age was 66 years (8.0; 51-84), mean PSA was 4.8 ng/ml (7.0; 0.3-70), mean prostate volume was 75.63 ml (42.1; 37-253), mean volume of prostatic tissue removed was 65.9 ml (35.8; 30-217). Mean surgical duration was 47.58 min (21.3; 15-120 min): enucleation

2019 World journal of urology

178. Cynomorium songaricum Rupr Demonstrates Phytoestrogenic or Phytoandrogenic like Activities that Attenuates Benign Prostatic Hyperplasia via Regulating Steroid 5-α-Reductase. (Abstract)

Cynomorium songaricum Rupr Demonstrates Phytoestrogenic or Phytoandrogenic like Activities that Attenuates Benign Prostatic Hyperplasia via Regulating Steroid 5-α-Reductase. Cynomorium songaricum Rupr. (CS) belongs to the genus of parasitic perennial flowering plants, mostly used in Chinese traditional medicine for benign prostatic hyperplasia (BPH) treatment. BPH is a chronic disease in men that both androgen and estrogen play a crucial role in promoting its development via their receptors (...) (ELISA). In vitro, human benign prostatic epithelial cell BPH-1 was cultured and treated with or without different CS compounds and DHT or E2. MTT and CCK-8 assays were performed to detect the regulatory effects on cell proliferation. The expressions of PCNA, AR, ERα, ERβ, and steroid 5-α-reductases (SRD5A1 and SRD5A2) were further analyzed by western blotting upon treatment.Treatment with CS significantly inhibited rat prostate enlargement, improved the pathological feature and reduced the thickness

2019 Journal of Ethnopharmacology

179. Chinese Skullcap (Scutellaria baicalensis Georgi) inhibits inflammation and proliferation on benign prostatic hyperplasia in rats. (Abstract)

Chinese Skullcap (Scutellaria baicalensis Georgi) inhibits inflammation and proliferation on benign prostatic hyperplasia in rats. Chinese Skullcap (Scutellaria baicalensis Georgi), which is part of the 50 fundamental herbs of Traditional Chinese Medicine, has been extensively used in the several East Asian countries to treat pyrexia, micturition disorder and inflammation. Although skullcap has effective properties on various diseases, the effects and molecular mechanism of Chinese Skullcap (...) -induced rats administrated with SRE 200 mg/kg/day. We measured the weight of prostate, and thickness of prostate using H&E staining. Western blotting, immunostaining and real-time PCR were used to measure proliferation- and inflammation-relative markers. To confirm the effects of SRE on apoptotic events in BPH-induced tissues, we performed the TUNEL assay.Compared with the untreated group, the SRE administration group suppressed pathological alterations, such as prostate growth and increase in serum

2019 Journal of Ethnopharmacology

180. Tamsulosin and Solifenacin in the Treatment of Benign Prostatic Hyperplasia in combination with overactive bladder. (Full text)

Tamsulosin and Solifenacin in the Treatment of Benign Prostatic Hyperplasia in combination with overactive bladder. To analyze the clinical effect of tamsulosin and Solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder and its safety. Another objective was to investigate the clinical effect and safety of mega dose of tamsulosin in the treatment of benign prostatic hyperplasia in combination with overactive bladder.One hundred and twenty-four (...) patients who were admitted to the Dept. of Urology at Binzhou People's Hospital, , China with confirmed benign prostatic hyperplasia (BPH) with overactive bladder were randomly divided into two groups. Sixty-two patients in the control group were treated with tamsulosin, while sixty-two patients in the observation group were treated with tamsulosin in combination with solifenacin. The treatment of both groups lasted for 12 weeks. The effect and adverse reaction were compared between the two groups.The

2019 Pakistan Journal Of Medical Sciences Controlled trial quality: uncertain PubMed abstract

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>